JP2015509110A5 - - Google Patents

Download PDF

Info

Publication number
JP2015509110A5
JP2015509110A5 JP2014555351A JP2014555351A JP2015509110A5 JP 2015509110 A5 JP2015509110 A5 JP 2015509110A5 JP 2014555351 A JP2014555351 A JP 2014555351A JP 2014555351 A JP2014555351 A JP 2014555351A JP 2015509110 A5 JP2015509110 A5 JP 2015509110A5
Authority
JP
Japan
Prior art keywords
tautomer
compound
pharmaceutically acceptable
alkyl
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014555351A
Other languages
English (en)
Japanese (ja)
Other versions
JP6002785B2 (ja
JP2015509110A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2013/050555 external-priority patent/WO2013114250A1/en
Publication of JP2015509110A publication Critical patent/JP2015509110A/ja
Publication of JP2015509110A5 publication Critical patent/JP2015509110A5/ja
Application granted granted Critical
Publication of JP6002785B2 publication Critical patent/JP6002785B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014555351A 2012-02-03 2013-01-22 ナトリウムチャネルモジュレーターとしてのベンゾイミダゾールおよびイミダゾピリジン誘導体 Expired - Fee Related JP6002785B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261594460P 2012-02-03 2012-02-03
US61/594,460 2012-02-03
PCT/IB2013/050555 WO2013114250A1 (en) 2012-02-03 2013-01-22 Benziimidazole and imidazopyridine derivatives as sodium channel modulators

Publications (3)

Publication Number Publication Date
JP2015509110A JP2015509110A (ja) 2015-03-26
JP2015509110A5 true JP2015509110A5 (enExample) 2016-02-12
JP6002785B2 JP6002785B2 (ja) 2016-10-05

Family

ID=47846092

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014555351A Expired - Fee Related JP6002785B2 (ja) 2012-02-03 2013-01-22 ナトリウムチャネルモジュレーターとしてのベンゾイミダゾールおよびイミダゾピリジン誘導体

Country Status (9)

Country Link
US (1) US8927587B2 (enExample)
EP (1) EP2809655B1 (enExample)
JP (1) JP6002785B2 (enExample)
AR (1) AR089865A1 (enExample)
CA (1) CA2861439C (enExample)
ES (1) ES2548228T3 (enExample)
TW (1) TW201341370A (enExample)
UY (1) UY34602A (enExample)
WO (1) WO2013114250A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2961403A4 (en) 2013-03-01 2016-11-30 Zalicus Pharmaceuticals Ltd HETEROCYCLIC INHIBITORS OF SODIUM CHANNEL
KR102435145B1 (ko) 2013-12-13 2022-08-24 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 피리돈 아미드의 프로드럭
EP3110799A4 (en) * 2014-02-27 2017-10-11 Epirus Biopharmaceuticals, Inc. Heterocyclic inhibitors of the sodium channel
EP3148992A1 (en) 2014-05-30 2017-04-05 Pfizer Inc. Benzenesulfonamides useful as sodium channel inhibitors
WO2016009303A1 (en) 2014-07-17 2016-01-21 Pfizer Inc. Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CN107922350B (zh) * 2015-09-11 2022-04-19 大日本住友制药株式会社 新的苯并咪唑化合物及其医药用途
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CA3063901A1 (en) 2017-05-16 2018-11-22 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
JPWO2018212162A1 (ja) * 2017-05-17 2020-03-19 株式会社トクヤマ ジアミノベンゼン化合物の製造方法
JP7277431B2 (ja) 2017-07-11 2023-05-19 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルのモジュレーターとしてのカルボキサミド
CA3088764A1 (en) * 2018-01-15 2019-07-18 UCB Biopharma SRL Fused imidazole derivatives as il-17 modulators
EP3752152A1 (en) 2018-02-12 2020-12-23 Vertex Pharmaceuticals Incorporated A method of treating pain
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US12440481B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
PH12022551379A1 (en) 2019-12-06 2023-05-03 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
CN115397826B (zh) * 2020-04-14 2025-07-15 宾夕法尼亚大学理事会 取代的{1,2,4,}三唑并{1,5-a}嘧啶化合物及其使微管稳定的应用
WO2022108849A1 (en) * 2020-11-17 2022-05-27 Arisan Therapeutics Inc. Heterocyclic compounds as therapeutic agents
CA3221938A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
KR20240031299A (ko) 2021-06-04 2024-03-07 버텍스 파마슈티칼스 인코포레이티드 (2r,3s,4s,5r)-4-[[3-(3,4-디플루오로-2-메톡시-페닐)-4,5-디메틸-5-(트리플루오로메틸)테트라하이드로푸란-2-카르보닐]아미노]피리딘-2-카르복사미드를 포함하는 고체 투여 형태 및 투여 요법
US20240294512A1 (en) 2021-06-04 2024-09-05 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
DK4347031T3 (da) 2021-06-04 2025-12-01 Vertex Pharma N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler
AU2022286438A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
WO2022256702A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
CN114249654B (zh) * 2021-12-30 2023-11-14 江苏广域化学有限公司 烷基苯胺类化合物的制备方法
CN116462662A (zh) 2022-01-18 2023-07-21 成都康弘药业集团股份有限公司 芳香并环类Nav1.8抑制剂及其用途
CN114288289A (zh) * 2022-02-17 2022-04-08 昆山彭济凯丰生物科技有限公司 具有镇痛和/或止痒功能的药物组合物及其应用
CR20240513A (es) 2022-04-22 2025-04-30 Vertex Pharma Compuestos de heteroarilo para el tratamiento del dolor
CA3256604A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated HETEROARYL COMPOUNDS FOR PAIN RELIEF
CA3257285A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated HETEROARYL COMPOUNDS FOR PAIN RELIEF
US20250388543A1 (en) 2022-04-22 2025-12-25 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
GEAP202516637A (en) 2022-04-25 2025-03-25 Siteone Therapeutics Inc Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
CN120603815A (zh) 2022-12-06 2025-09-05 沃泰克斯药物股份有限公司 钠通道的取代四氢呋喃调节剂的合成方法
CN116621789A (zh) * 2023-05-31 2023-08-22 上海吉奉生物科技有限公司 一种(4s)-3-[2-[[芴甲氧羰基]氨基]乙酰基]-2,2-二甲基-4-恶唑烷羧酸的合成方法
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
TW202535867A (zh) 2023-10-23 2025-09-16 美商維泰克斯製藥公司 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
TW202523313A (zh) 2023-10-23 2025-06-16 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain
WO2025160286A1 (en) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
US20260001877A1 (en) 2024-06-28 2026-01-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8604566D0 (sv) * 1986-10-27 1986-10-27 Haessle Ab Novel compunds
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
CA2425185A1 (en) * 2000-10-06 2002-04-11 Stephane De Lombaert Benzimidazole and indole derivatives as crf receptor modulators
EA200500289A1 (ru) * 2002-07-31 2005-06-30 Еуро-Селтик С. А. Арилзамещенные бензимидазолы и их использование в качестве блокаторов натриевых каналов
AU2004283751B2 (en) * 2003-10-24 2011-05-19 Exelixis, Inc. p70S6 kinase modulators and method of use
WO2005113580A1 (en) 2004-05-21 2005-12-01 Pfizer Inc. Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
JP2009532381A (ja) * 2006-03-31 2009-09-10 アストラゼネカ アクチボラグ 二環式ベンズイミダゾール化合物、および代謝型グルタミン酸受容体増強剤としての該化合物の使用
SI2076508T1 (sl) 2006-10-18 2011-04-29 Pfizer Prod Inc Spojine biaril eter sečnine
US20080207683A1 (en) * 2007-02-15 2008-08-28 Darin Allen Biaryl-substituted tetrahydro-pyrazolo-pyridine modulators of cathepsin s
WO2008118758A1 (en) 2007-03-23 2008-10-02 Icagen, Inc. Inhibitors of ion channels
CA2685952C (en) 2007-05-03 2012-03-13 Pfizer Limited N- [6-amino-5- (phenyl) pyrazin-2-yl] -isoxazole-4-carboxamide derivatives and related compounds as nav1.8 channel modulators for the treatment of pain
AP2516A (en) 2007-05-03 2012-11-26 Pfizer Ltd 2-Pyridine carboxamide derivatives as sodium channel modulators
JP5460589B2 (ja) 2007-07-13 2014-04-02 アイカジェン, インコーポレイテッド ナトリウムチャネル阻害物質
WO2009079011A1 (en) * 2007-12-19 2009-06-25 The Scripps Research Institute Benzimidazoles and analogs as rho kinase inhibitors
EP2072516A1 (en) * 2007-12-21 2009-06-24 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as Melancortin-4 receptor antagonists
US8628695B2 (en) 2008-04-18 2014-01-14 E I Du Pont De Nemours And Company Surface-modified ruthenium oxide conductive material, lead-free glass(es), thick film resistor paste(s), and devices made therefrom
EP2364089B1 (en) * 2008-10-30 2016-12-07 Biogen MA Inc. Heterobicyclic sphingosine 1-phosphate analogs
JP5667934B2 (ja) * 2010-06-28 2015-02-12 大日本住友製薬株式会社 新規2環性複素環化合物からなる医薬
WO2012116440A1 (en) 2011-03-03 2012-09-07 Zalicus Pharmaceuticals Ltd. Benzimidazole inhibitors of the sodium channel

Similar Documents

Publication Publication Date Title
JP2015509110A5 (enExample)
JP2018537413A5 (ja) 化合物、医薬的に許容される塩又はその立体異性体及び医薬組成物
JP2014506907A5 (enExample)
RU2015149527A (ru) Производные доластатина 10 и ауристатинов
JP2014511891A5 (enExample)
JP2016514159A5 (enExample)
JP2016503799A5 (enExample)
JP2013537203A5 (enExample)
JP2010524932A5 (enExample)
JP2015520140A5 (enExample)
JP2014507455A5 (enExample)
JP2014508811A5 (enExample)
JP2019516739A5 (enExample)
JP2014508804A5 (enExample)
JP2015516427A5 (enExample)
JP2016516043A5 (enExample)
JP2015504081A5 (enExample)
JP2013056919A5 (enExample)
JP2012506896A5 (enExample)
JP2013508279A5 (enExample)
JP2012092103A5 (enExample)
JP2011527299A5 (enExample)
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
RU2016104844A (ru) Производные n-мочевино замещенных аминокислот как модуляторы формил-пептидного рецептора
JP2013537240A5 (enExample)